These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 28011045)

  • 1. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
    Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
    Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
    BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (
    Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
    Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Reyhan M; Parlak C; Guler OC; Oymak E
    Int J Gynecol Cancer; 2013 Jul; 23(6):1104-10. PubMed ID: 23792605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer.
    Ho JC; Fang P; Cardenas CE; Mohamed ASR; Fuller CD; Allen PK; Bhosale PR; Frumovitz MM; Jhingran A; Klopp AH
    Radiother Oncol; 2019 Jun; 135():58-64. PubMed ID: 31015171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting tumor recurrence in patients with cervical carcinoma treated with definitive chemoradiotherapy: value of quantitative histogram analysis on diffusion-weighted MR images.
    Erbay G; Onal C; Karadeli E; Guler OC; Arica S; Koc Z
    Acta Radiol; 2017 Apr; 58(4):481-488. PubMed ID: 27445314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment response evaluation using the mean apparent diffusion coefficient in cervical cancer patients treated with definitive chemoradiotherapy.
    Onal C; Erbay G; Guler OC
    J Magn Reson Imaging; 2016 Oct; 44(4):1010-9. PubMed ID: 26919800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole lesion histogram analysis of apparent diffusion coefficients on MRI predicts disease-free survival in locally advanced squamous cell cervical cancer after radical chemo-radiotherapy.
    Zhao B; Cao K; Li XT; Zhu HT; Sun YS
    BMC Cancer; 2019 Nov; 19(1):1115. PubMed ID: 31729974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.
    Gu KW; Kim CK; Choi CH; Yoon YC; Park W
    Eur Radiol; 2019 Nov; 29(11):6236-6244. PubMed ID: 30980126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Radiation Field Failure After Definitive Chemoradiation in Patients With Locally Advanced Cervical Cancer.
    Bae HS; Kim YJ; Lim MC; Seo SS; Park SY; Kang S; Kim SH; Kim JY
    Int J Gynecol Cancer; 2016 May; 26(4):737-42. PubMed ID: 26937749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients.
    Heo SH; Shin SS; Kim JW; Lim HS; Jeong YY; Kang WD; Kim SM; Kang HK
    Korean J Radiol; 2013; 14(4):616-25. PubMed ID: 23901319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.
    Bacorro W; Dumas I; Escande A; Gouy S; Bentivegna E; Morice P; Haie-Meder C; Chargari C
    Gynecol Oncol; 2018 Mar; 148(3):461-467. PubMed ID: 29325690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic values of ADC
    Akkus Yildirim B; Onal C; Erbay G; Cem Guler O; Karadeli E; Reyhan M; Koc Z
    J Obstet Gynaecol; 2019 Feb; 39(2):224-230. PubMed ID: 30354907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).
    Mell LK; Sirák I; Wei L; Tarnawski R; Mahantshetty U; Yashar CM; McHale MT; Xu R; Honerkamp-Smith G; Carmona R; Wright M; Williamson CW; Kasaová L; Li N; Kry S; Michalski J; Bosch W; Straube W; Schwarz J; Lowenstein J; Jiang SB; Saenz CC; Plaxe S; Einck J; Khorprasert C; Koonings P; Harrison T; Shi M; Mundt AJ;
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):536-545. PubMed ID: 28126303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes on Midchemoradiation Therapy Fluorodeoxyglucose Positron Emission Tomography for Cervical Cancer Are Associated with Prognosis.
    Carpenter DJ; Jacobs CD; Wong TZ; Craciunescu O; Chino JP
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):356-366. PubMed ID: 31254659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can diffusion-weighted magnetic resonance imaging predict tumor recurrence of uterine cervical cancer after concurrent chemoradiotherapy?
    Bae JM; Kim CK; Park JJ; Park BK
    Abdom Radiol (NY); 2016 Aug; 41(8):1604-10. PubMed ID: 27056747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximum standardized lymph node uptake value could be an important predictor of recurrence and survival in patients with cervical cancer.
    Nakamura K; Joja I; Nagasaka T; Haruma T; Hiramatsu Y
    Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():77-82. PubMed ID: 24275232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.